Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Laboratory Co. of America Holdings NYSE: LH. In a filing disclosed on May 31st, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
- Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
- Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
- Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
- Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
- Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
Laboratory Co. of America Price Performance
Shares of Laboratory Co. of America stock traded up $3.92 during trading on Wednesday, reaching $254.43. The company's stock had a trading volume of 892,607 shares, compared to its average volume of 636,799. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12-month low of $192.38 and a 12-month high of $258.59. The company has a market capitalization of $21.30 billion, a P/E ratio of 28.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.82. The business has a 50 day moving average price of $235.99 and a 200-day moving average price of $238.48.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, beating analysts' consensus estimates of $3.73 by $0.11. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The firm had revenue of $3.35 billion for the quarter, compared to the consensus estimate of $3.41 billion. During the same period in the previous year, the business earned $3.68 earnings per share. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.
Laboratory Co. of America Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.13%. Laboratory Co. of America's dividend payout ratio (DPR) is currently 33.29%.
Hedge Funds Weigh In On Laboratory Co. of America
A number of institutional investors have recently made changes to their positions in LH. Norges Bank acquired a new position in shares of Laboratory Co. of America in the fourth quarter worth $239,811,000. Select Equity Group L.P. increased its stake in Laboratory Co. of America by 150.9% in the fourth quarter. Select Equity Group L.P. now owns 1,595,957 shares of the medical research company's stock valued at $365,985,000 after purchasing an additional 959,981 shares during the last quarter. Amundi increased its stake in Laboratory Co. of America by 344.9% in the fourth quarter. Amundi now owns 1,123,409 shares of the medical research company's stock valued at $263,161,000 after purchasing an additional 870,903 shares during the last quarter. GAMMA Investing LLC increased its stake in Laboratory Co. of America by 37,334.2% in the first quarter. GAMMA Investing LLC now owns 809,702 shares of the medical research company's stock valued at $188,450,000 after purchasing an additional 807,539 shares during the last quarter. Finally, Madison Investment Advisors LLC acquired a new position in Laboratory Co. of America in the fourth quarter valued at $123,415,000. 95.94% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Laboratory Co. of America
In related news, CEO Adam H. Schechter sold 6,105 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $248.73, for a total value of $1,518,496.65. Following the completion of the transaction, the chief executive officer now directly owns 98,962 shares in the company, valued at approximately $24,614,818.26. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Amy B. Summy sold 758 shares of the company's stock in a transaction on Friday, March 28th. The shares were sold at an average price of $231.67, for a total value of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares of the company's stock, valued at $1,228,314.34. The trade was a 12.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,592 shares of company stock worth $2,347,820. 0.84% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities analysts recently issued reports on LH shares. Jefferies Financial Group lifted their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Robert W. Baird lifted their price objective on Laboratory Co. of America from $253.00 to $267.00 and gave the stock an "outperform" rating in a report on Wednesday, April 30th. Truist Financial lifted their price objective on Laboratory Co. of America from $274.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Redburn Atlantic started coverage on Laboratory Co. of America in a report on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price objective for the company. Finally, Barclays lifted their price objective on Laboratory Co. of America from $240.00 to $250.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $272.92.
Check Out Our Latest Stock Report on LH
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Laboratory Co. of America
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Read More
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
